Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models

KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer

(2019) He Cheng et al.   CANCER LETTERS

RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers

(2019) Hanchen Xu et al.   Molecular Cancer

Targeting the untargetable KRAS in cancer therapy

(2019) Pingyu Liu et al.   Acta Pharmaceutica Sinica B

IFNγ, a Double-Edged Sword in Cancer Immunity and Metastasis

(2019) Chengfei Liu et al.   CANCER RESEARCH

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

(2019) Wenting Liao et al.   CANCER CELL

Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator

(2019) Jing Pan et al.   EBioMedicine

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine

(2018) Chao Cheng et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations

(2018) Allen Cohn et al.   JOURNAL OF IMMUNOTHERAPY

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

(2018) Jasmin Quandt et al.   OncoImmunology

Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models

(2016) Aizhang Xu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation as a driver and vulnerability of KRAS mediated oncogenesis

(2016) Shunsuke Kitajima et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

(2016) S. Zdanov et al.   Cancer Immunology Research

A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice

(2016) Li Zhang et al.   PLoS One

Reviewing Peer Review at the NIH

(2015) Michael S. Lauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

(2015) Q. J. Wang et al.   Cancer Immunology Research

A Fully Synthetic Four-Component Antitumor Vaccine Consisting of a Mucin Glycopeptide Antigen Combined with Three Different T-Helper-Cell Epitopes

(2014) Björn Palitzsch et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

(2014) John C Castle et al.   BMC GENOMICS

Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer

(2014) Hideki Kimura et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

(2014) Jamie E. Chaft et al.   Clinical Lung Cancer

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

(2014) T-Y Weng et al.   GENE THERAPY

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

(2014) Osama E Rahma et al.   Journal of Translational Medicine

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Vaccine therapy for pancreatic cancer

(2014) Bulent Salman et al.   OncoImmunology

Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity

(2013) R. Perret et al.   CANCER RESEARCH

Mutant KRAS is a druggable target for pancreatic cancer

(2013) E. Zorde Khvalevsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants

(2013) Harm HogenEsch   Frontiers in Immunology

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment

(2011) M. Grimm et al.   CELLULAR ONCOLOGY

IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines

(2010) Kaustuv Banerjee et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

(2010) Ghassan K. Abou-Alfa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY